EpiCast Report: Melanoma - Epidemiology Forecast to 2026
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013).
In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagnosed prevalent cases of melanoma in the 7MM are also expected to increase from almost 0.75 million cases in 2016 to over 900,000 cases in 2026 at an AGR of over 2.5%.
Australia has the highest age-standardized incidence rate of melanoma in the 7MM by a significant margin. In 2016, incidence of melanoma in Australian men was over 60 cases per 100,000, and over 41.59 cases per 100,000 in Australian women. The second highest age-standardized incidence of melanoma in men was in the US, at about 30 cases per 100,000 of its population. The UK had the second highest incidence rate in women, at about 20 cases per 100,000. Over the forecast period, the age-standardized incidence rates of melanoma will remain largely unchanged, with the greatest growth seen in Germany from 2006-2011.
The report EpiCast Report: Melanoma - Epidemiology Forecast to 2026, provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).
The Melanoma EpiCast Report provides an overview of the risk factors and global trends of melanoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).
The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buyThe Melanoma EpiCast report will allow you to -
Develop business strategies by understanding the trends shaping and driving the global melanoma market.
Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for melanoma therapeutics in each of the markets covered.
Compare patient population potentials by age, sex, stage at diagnosis, and survival.